Virtual screening method and application of STAT3 inhibitor with anti-tumor efficacy
Through STAT3 protein structure pretreatment and virtual screening workflow, combined with MM/GBSA and molecular dynamics simulation, compounds with anti-tumor and STAT3 inhibition were screened, solving the problem of poor activity of existing STAT3 inhibitors and achieving high efficiency Screening of STAT3 target antitumor drugs.
Patent Information
- Application Number
- CN202411152487.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-21
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2044-08-21
Smart Images

Figure CN119091978A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of medicinal chemistry, and in particular to a virtual screening method and application of a STAT3 inhibitor with anti-tumor efficacy. Background Art
[0002] Signal transducer and activator of transcription (STAT) consists of seven members: STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b and STAT6. They are an important class of transcription factors that are involved in multiple biological processes such as cell cycle, differentiation, proliferation and apoptosis, and have the dual functions of signal transduction and transcriptional regulation (Huynh, J.; Chand, A.; Gough, D.; Ernst, M. Therapeutically exploiting STAT3 activity in cancer–using tissue repair as a road map[J]. Nat. Rev. Cancer 2019, 19, 82-96. Zhao, C.; Li, H.; Lin, HJ; Yang, S.; Lin, J.; Liang, G. Feedback activation of STAT3 as a cancer drug-resistance mechanism[J]. Trends. Pharmacol. Sci. 2016, 37, 47-61.). Although highly homologous in structure, they usually act on different cellular processes. Studies have shown that STAT3 plays an important role in the early and progressive stages of cancer and in the tumor microenvironment. Abnormal activation of STAT3 is closely related to the proliferation, invasion and metastasis of tumor cells, and has therefore received great attention (Johnson, DE; O'Keefe, RA; Grandis, JR Targeting the IL-6 / JAK / STAT3 signaling axis in cancer [J]. Nat. Rev. Clin. Oncol. 2018, 15, 234-248.). Hyperphosphorylation of STAT3 has been detected in a variety of tumor cell lines and clinical samples, including breast cancer, pancreatic cancer, gastric cancer, etc. Therefore, inhibiting the activation or expression of STAT3 is an effective way to treat various cancers.
[0003] Although STAT3 has become a hot topic in the development of anti-tumor drugs as an emerging target, there are currently no drugs on the market and only a few drugs are in the clinical trial stage. AZD9150 is a 16-nucleotide antisense oligonucleotide that indirectly downregulates the expression level of STAT3 protein by downregulating STAT3 mRNA. The compound is currently in Phase 2 clinical trials and is mainly used in combination with durvalumab for the treatment of solid tumors (Reilley, MJ; McCoon, P.; Cook, C.; Lyne, P.; Kurzrock, R.; Kim, Y.; Woessner, R.; Younes, A.; Nemunaitis, J.; Fowler, N.; Curran, M.; Liu, Q.; Zhou, T.; Schmidt, J.; Jo, M.; Lee, S.J.; Yamashita, M.; Hughes, S.G.; Fayad, L.; Piha-Paul, S.; Nadella, MVP; Xiao, X.; Hsu, J.; Revenko, A.; Monia, BP; MacLeod, AR; Hong, D.S. STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1btrial[J].J.Immunother.Cancer 2018,6,119.). Napabucasin is an oral STAT3 inhibitor that blocks cancer metastasis and recurrence by inhibiting tumor stemness pathways. Currently, several phase 3 clinical trials for cancer treatment are underway (Hanafi, M.; Chen, X.; Neamati, N. Discovery of a Napabucasin PROTAC as an effective degrader of the E3 ligase ZFP91[J].J.Med.Chem.2021,64,1626-1648.).STA-21 can inhibit the DNA binding activity, dimerization and STAT3-dependent luciferase activity of STAT3 (Ahmad, SF; Ansari, MA; Nadeem, A.; Zoheir, KMA; Bakheet, SA; Alsaad, AMS; Al-Shabanah, OA; Attia, SMST A-21, a STAT-3 inhibitor, attenuates the development and progression of inflammation in collagen antibody-induced arthritis[J]. Immunobiology 2017, 222, 206-217.). Pyrimethamine is a clinically used antiparasitic drug. It was first discovered in 2011 that it can inhibit the function of STAT3 and inhibit the growth of breast cancer in vivo (Khan, MW; Saadalla, A.; Ewida, AH; Al-Katranji, K.; Al-Saoudi, G.; Giaccone, ZT; Gounari, F.; Zhang, M.; Frank, DA; Khazaie, K. The STAT3 inhibitor pyrimethamine displays anti-cancer and immune stimulatory effects in murine models of breast cancer [J]. Cancer Immunol. Immunother. 2018, 67, 13-23.). Although more and more clinical trials have confirmed the superiority of STAT3 targeted therapy, very few STAT3 inhibitors have entered clinical research, and the activity of existing small molecule STAT3 inhibitors is mostly poor. Therefore, the development of new STAT3 inhibitors with better activity and higher specificity is of great scientific significance.
[0004] Virtual screening refers to the pre-screening of compound molecules on a computer according to pre-set conditions before biological activity screening to identify the small molecules that are most likely to bind to the target, thereby greatly reducing the number of actual screening compounds and improving the efficiency of lead compound discovery. Computer-aided drug design uses various molecular simulation technologies and theoretical calculation methods to greatly accelerate the screening of drug molecular models. The three-dimensional structures of many biological macromolecules have been analyzed, making computer-aided drug design based on protein receptor structures more realistic. Compared with traditional drug screening methods, virtual screening can not only shorten the drug development cycle, but also reduce the cost of drug development. Therefore, it is imperative to establish an efficient and rapid screening method for anti-tumor drugs targeting STAT3 to discover more possible STAT3 inhibitors. Summary of the invention
[0005] In view of the above technical problems and deficiencies in the art, the present invention provides a virtual screening method and application of STAT3 inhibitors with anti-tumor efficacy.
[0006] The present invention provides a rapid virtual screening method for anti-tumor drugs targeting STAT3, and a novel STAT3 inhibitor with significant anti-tumor effect and STAT3 phosphorylation inhibition effect is obtained through this screening process. The present invention can provide a reference for the screening of STAT3 inhibitors with anti-tumor effect.
[0007] The present invention provides an implementation scheme for rapid screening of anti-tumor drugs targeting STAT3. The screened compounds have significant anti-tumor effects and STAT3 inhibitory effects, and can be used to develop drugs for treating anti-tumor or STAT3 inhibition-related diseases.
[0008] In a first aspect, the present invention provides a virtual screening method for STAT3 inhibitors having anti-tumor efficacy, comprising the steps of:
[0009] (1) Selection and preprocessing of STAT3 protein crystal structure: Obtain the STAT3 protein-small molecule complex crystal structure from the Protein Data Bank database and preprocess the STAT3 protein-small molecule complex crystal structure;
[0010] (2) Generate docking box: Select the docking box center and set the docking box size;
[0011] (3) Select and download the compound library to be screened;
[0012] (4) Compound virtual screening workflow: Compounds with high binding free energy scores are obtained by performing compound library preprocessing, multi-mode molecular docking, and MM / GBSA calculation re-scoring and sorting in a virtual screening workflow mode; the high binding free energy score means that the binding free energy is negative and the absolute value is ranked high from large to small;
[0013] (5) Molecular dynamics simulation to further screen active molecules: Binding Pose Metadynamics (BPMD) molecular dynamics simulation method is used to further screen and obtain compounds with potential activity.
[0014] In step (1), the STAT3 protein-small molecule complex crystal structure may be a complex crystal structure of human STAT3 protein and small molecule SD-36.
[0015] In step (1), the Protein Preparation Workflow module can be used to pre-process the STAT3 protein-small molecule complex crystal structure.
[0016] In step (1), the pretreatment may include one or more of deleting solvent molecules, adding hydrogen, repairing missing residues and side chains, protonating protein residues, optimizing hydrogen bond networks, minimizing energy, and repairing incorrect atom types.
[0017] In step (2), the Receptor Grid Generation module can be used to generate a docking box, the position of the docking box can be set with the ligand small molecule in the STAT3 protein-small molecule complex crystal structure as the center, and the box size can be set with the ligand small molecule in the STAT3 protein-small molecule complex crystal structure as a reference.
[0018] In step (3), you can select the ChemDiv compound library and download all the molecular 3D structures therein.
[0019] In step (4), the compound virtual screening workflow can be performed in the Virtual Screening Workflow module: the compound library is first filtered by the QikProp module to ensure that the screened compounds have good pharmacokinetic characteristics and physicochemical properties. The filtered molecules are protonated and stereochemical information is obtained by the LigPrep module, and then enter the molecular docking stage. The screened compounds are obtained through three stages of molecular docking screening, namely high throughput virtual screening (HTVS), standard precision screening (SP), and extra precision screening (XP). The binding free energy of these screened compounds is calculated by the MM / GBSA method and re-scored and sorted. According to the MM / GBSA ΔG bind score (binding free energy) <-50 kcal / mol to screen out compounds with high binding free energy scores.
[0020] The virtual screening method may further include, between step (4) and step (5), classifying and grouping the compounds with higher binding free energy scores obtained in step (4).
[0021] Furthermore, the classification and grouping may include: performing structural classification of compounds in a Ligand Filtering module according to the functional group type, and then selecting compounds with high binding free energy scores to perform the molecular dynamics simulation of step (5).
[0022] In step (5), the molecular dynamics simulation uses the Binding Pose Metadynamics module. Each protein-ligand docking complex undergoes a round of 10×10 ns molecular dynamics simulation. The simulated CompScore (CompScore=PoseScore-5×PersScore) values are then sorted again from small to large to screen out the top-ranked molecules as potentially active compounds.
[0023] In a second aspect, the present invention provides the use of compounds a5, a6, a7, a10, b4, b9, b11, d2, d3, d10, d29 or pharmaceutically acceptable salts thereof having the following structures in the preparation of STAT3 inhibitors:
[0024]
[0025] In a third aspect, the present invention provides the use of compounds a5, a6, a7, a10, b4, b9, b11, d2, d3, d10, d29 or pharmaceutically acceptable salts thereof having the following structures in the preparation of a drug for treating and / or preventing a disease associated with abnormal STAT3 activity:
[0026]
[0027] In the application described in the third aspect, the diseases include breast cancer, gastric cancer, prostate cancer, lung cancer, pancreatic cancer, etc.
[0028] Compared with the prior art, the present invention has the following beneficial effects:
[0029] The screening implementation scheme of the anti-tumor drug with STAT3 as the target involved in the present invention is simple, rapid and efficient, and has a high probability of screening positive compounds. The screened compounds have significant anti-tumor and STAT3 inhibitory effects. BRIEF DESCRIPTION OF THE DRAWINGS
[0030] Figure 1 Schematic diagram of the virtual screening process for STAT3 inhibitors.
[0031] Figure 2 The activity verification results of the screened compounds in Example 2 and the positive control drugs NP (Napabucasion, or NAPA for short) and BP (BP-1-102) are shown.
[0032] Figure 3 This is a graph showing the results of the STAT3 inhibitory effect analysis of compound d2.
[0033] Figure 4 This is a graph showing the results of the STAT3 inhibitory effect analysis of compound d10. DETAILED DESCRIPTION
[0034] The present invention will be further described below in conjunction with the accompanying drawings and specific embodiments. It should be understood that these embodiments are only used to illustrate the present invention and are not used to limit the scope of the present invention.
[0035] Example 1 Virtual Screening Process
[0036] See also Figure 1 , a virtual screening method for STAT3 inhibitors with anti-tumor efficacy, comprising:
[0037] Step (1), selection and preprocessing of STAT3 protein crystal structure: The crystal structure of the complex of human STAT3 protein and small molecule was obtained from the Protein Data Bank database, which is the crystal structure of the complex of STAT3 protein and small molecule SD-36 (PDB: 6NJS). The protein preparation workflow module was used to preprocess the protein-ligand complex structure, including deleting solvent molecules, hydrogenation, repairing missing residues and side chains, protonating protein residues, optimizing hydrogen bond networks, and minimizing energy.
[0038] Step (2), generate a docking box: Use the Receptor Grid Generation module to generate a docking box. Set the position of the docking box with the ligand small molecule SD-36 in the crystal structure of the STAT3 protein complex as the center, set the box size with the ligand molecule as the reference, and set the other parameters as default.
[0039] Step (3), select and download the compound library to be screened: Select the ChemDiv compound library and download the 3D structures of all small molecules in the screening compound library from its official website (https: / / www.chemdiv.com / ), a total of 1,666,973 molecules (as of March 2024).
[0040] Step (4), compound virtual screening workflow: The compound virtual screening workflow is carried out in the Virtual ScreeningWorkflow module: the ChemDiv 3D database is first filtered by the QikProp module to ensure that the screened compounds have good pharmacokinetic characteristics and physicochemical properties; the filtered molecules are protonated by the LigPrep module to obtain stereochemical information (obtained from the 3D configuration of each small molecule); then enter the molecular docking stage, and successively retain the top 20% of the conformational molecules through high throughput virtual screening (HTVS), the top 10% of the conformational molecules through standard precision screening (SP), and the top 5% of the conformational molecules through extra precision screening (XP), a total of three stages of molecular docking screening to obtain 1666 compounds; the screened molecules are calculated by the MM / GBSA method for binding free energy and re-scored and sorted according to the MM / GBSA ΔG bind341 compounds with score < -50 kcal / mol were screened out for further analysis. This virtual screening workflow model sequentially undergoes compound library preprocessing, multi-mode molecular docking, and MM / GBSA calculation re-scoring and sorting to finally obtain compounds with high binding free energy scores. The high binding free energy score means that the binding free energy is negative and the absolute value is ranked high from large to small.
[0041] Step (5), compound classification and grouping: The structural classification of the compounds is performed manually in the Ligand Filtering module according to the type of functional group of interest, and then the compounds with high binding free energy scores are selected for molecular dynamics simulation to check the stability of the compound binding to the STAT3 protein to determine the most promising candidate molecules.
[0042] Step (6), molecular dynamics simulation further screens active molecules: Binding Pose Metadynamics (BPMD) is an enhanced sampling method that can effectively evaluate the binding stability of ligands to proteins in solution. The simulation was performed in the Binding Pose Metadynamics module, and each protein-ligand complex underwent a round of 10×10ns molecular dynamics simulation. The simulation time for each complex was approximately 5 hours on a single GPU graphics card (NVIDIA RTX 4090), and a total of 61 protein-ligand complexes were simulated. The simulation time varies for different graphics card models. According to the CompScore value (CompScore = PoseScore-5×PersScore) obtained by the simulation, the compounds were sorted again from small to large, and the top-ranked molecules were selected for purchase and experimental activity verification. Finally, 11 compounds a5, a6, a7, a10, b4, b9, b11, d2, d3, d10, and d29 with the following structures were successfully purchased for activity verification:
[0043]
[0044] Example 2 Cytotoxicity Evaluation
[0045] Cell activity evaluation CCK8 method was used to detect the proliferation inhibition of compounds on human breast cancer cells MDA-MB-231 and MDA-MB-468. The specific operation process is as follows:
[0046] Take tumor cells in the logarithmic growth phase, prepare a cell suspension, inoculate 100 μL / well (about 3000 cells) in a 96-well plate, set up 3 replicate wells in parallel, and culture in a 37°C incubator containing 5% CO2 for 24 hours. Dissolve the compound to be tested in DMSO to prepare a mother solution with a concentration of 10mM, and dilute the mother solution with cell culture medium. After removing the culture plate, add different concentrations of the sample to be tested to each well, set up 3 replicate wells in parallel, and continue to culture in a CO2 incubator for 72 hours. Remove the culture plate, add 10 μL of CCK8 solution to each well, and incubate in a 37°C incubator containing 5% CO2 for 1 to 2 hours. Place it in an ELISA reader to measure the absorbance (OD value) of each well at 450nm.
[0047] The inhibition rate of drug on cell proliferation was calculated according to the OD value. The formula is as follows:
[0048] Cell survival rate (%) = (OD sample -OD blank ) / (OD control -OD blank )×100%;
[0049] Cell inhibition rate (%) = (OD control -OD sample ) / (OD control -OD blank )×100%;
[0050] OD sample : OD value of the experimental well;
[0051] OD control : OD value of control well;
[0052] OD blank : OD value of blank well.
[0053] The half inhibition concentration IC was obtained by fitting the inhibition rate of each concentration 50 value.
[0054] Figure 2 The activity verification results of the screened compounds in Example 2 and the positive control drugs NP (Napabucasion) and BP (BP-1-102) are shown. Figure 2 The results showed that most of the 11 compounds had different degrees of proliferation inhibition on tumor cells MDA-MB-231 and MDA-MB-468, among which compounds d2 and d10 had the best inhibitory effects, which were comparable to those of the positive control drugs NP (Napabucasion) and BP (BP-1-102).
[0055] Example 3 Western Blot Analysis of STAT3 Protein Inhibition
[0056] Take cells in the logarithmic growth phase and inoculate them into 6-well plates. After overnight culture, replace the culture medium and treat with the specified concentration of compounds for 24 hours. After the culture is completed, wash with pre-cooled PBS 2 to 3 times and discard the PBS. Refer to the instructions of the whole protein extraction kit for cell protein extraction: add the calculated cell lysate to each well, scrape the cells with a cell scraper on ice, transfer the scraped cell lysate into the EP tube, and invert and lyse for 20 to 30 minutes. After the lysis is completed, centrifuge the cell lysate at 4°C 12000g for 30 minutes, transfer the supernatant into a new EP tube, and perform protein quantification or denaturation for protein experiments. The protein concentration was determined and calculated using the BCA protein quantification kit. The gel was configured with a gel fast kit for SDS-PAGE gel electrophoresis. After completion, the membrane was transferred. After the transfer was completed, the PDVF membrane was removed, the PVDF membrane was cut according to the marker position and the required protein, and it was immersed in the blocking solution for 5 to 15 minutes. Dilute the primary antibody in proportion with the primary antibody diluent, remove the blocking solution and add the prepared corresponding primary antibody, and incubate on a shaker at 4°C overnight. Recover the primary antibody and wash the PVDF membrane 3 times with TBST. Remove TBST and add the prepared corresponding secondary antibody, and incubate on a shaker at room temperature for 1 hour. Recover the secondary antibody and wash the PVDF membrane 3 times with TBST. Select the corresponding exposure method according to the secondary antibody to expose the washed PVDF membrane and save the image.
[0057] Figure 3 A graph showing the results of the STAT3 inhibition analysis of compound d2.
[0058] Figure 4 A graph showing the results of the STAT3 inhibition analysis of compound d10.
[0059] Figure 3 The results showed that compound d2 at a concentration of 40 μM could significantly downregulate the phosphorylation expression level of STAT3 (705) protein in both MDA-MB-468 and MDA-MB-231 breast cancer cells, but had no significant effect on the phosphorylation expression level of STAT3 (727) and the expression level of STAT3 background protein.
[0060] Figure 4 The results showed that compound d10 at a concentration of 50 μM could significantly downregulate the phosphorylation expression level of STAT3 (705) protein in MDA-MB-468 breast cancer cells, and also downregulate the expression level of STAT3 background protein, but had no significant effect on the phosphorylation expression level of STAT3 (727). In MDA-MB-231 cells, the inhibitory effect of compound d10 on STAT3 protein was not obvious.
[0061] In summary, STAT3 plays an important role in the early stage and progression of cancer as well as in the tumor microenvironment, and the abnormal activation of STAT3 is closely related to the proliferation, invasion and metastasis of tumor cells. Hyperphosphorylation of STAT3 has been detected in a variety of tumor cell lines and clinical samples, including breast cancer, pancreatic cancer, gastric cancer, etc., so inhibiting the activation or expression of STAT3 is an effective way to treat various cancers. The present invention provides an implementation scheme for rapid screening of anti-tumor drugs targeting STAT3, and the screened compounds have obvious anti-tumor effects and STAT3 inhibitory effects. The compounds obtained by the present invention can be used as lead compounds to further optimize and develop drugs for the treatment of malignant tumors or diseases related to abnormal expression of STAT3.
[0062] In addition, it should be understood that after reading the above description of the present invention, those skilled in the art may make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the claims attached to this application.
Claims
1. A virtual screening method for STAT3 inhibitors with anti-tumor efficacy, characterized in that: Includes steps: (1) Selection and preprocessing of STAT3 protein crystal structure: Obtain the STAT3 protein-small molecule complex crystal structure from the Protein Data Bank database and preprocess the STAT3 protein-small molecule complex crystal structure; (2) Generate docking box: Select the docking box center and set the docking box size; (3) Select and download the compound library to be screened; (4) Compound virtual screening workflow: Compounds with high binding free energy scores are obtained by performing compound library preprocessing, multi-mode molecular docking, and MM / GBSA calculation re-scoring and sorting in a virtual screening workflow mode; the high binding free energy score means that the binding free energy is negative and the absolute value is ranked high from large to small; (5) Molecular dynamics simulation to further screen active molecules: Binding Pose Metadynamics molecular dynamics simulation method is used to further screen for compounds with potential activity.
2. The virtual screening method according to claim 1, characterized in that In step (1): The STAT3 protein-small molecule complex crystal structure is a complex crystal structure of human STAT3 protein and small molecule SD-36; The Protein Preparation Workflow module was used to preprocess the STAT3 protein-small molecule complex crystal structure; The pretreatment includes one or more of deleting solvent molecules, adding hydrogen, repairing missing residues and side chains, protonating protein residues, optimizing hydrogen bond networks, minimizing energy, and repairing incorrect atom types.
3. The virtual screening method according to claim 1 or 2, characterized in that: In step (2), the ReceptorGrid Generation module is used to generate a docking box, the position of the docking box is set with the ligand small molecule in the crystal structure of the STAT3 protein-small molecule complex as the center, and the box size is set with the ligand small molecule in the crystal structure of the STAT3 protein-small molecule complex as the reference.
4. The virtual screening method according to claim 1, characterized in that In step (3), select the ChemDiv compound library and download all the molecular 3D structures therein.
5. The virtual screening method according to claim 1 or 4, characterized in that: In step (4), the compound virtual screening workflow is carried out in the Virtual Screening Workflow module: the compound library is first filtered by the QikProp module to ensure that the screened compounds have good pharmacokinetic characteristics and physicochemical properties. The filtered molecules are protonated and stereochemical information is obtained by the LigPrep module, and then enter the molecular docking stage. The screened compounds are obtained through three stages of molecular docking screening, namely high-throughput screening, standard precision screening, and high-precision screening. The binding free energy of these screened compounds is calculated by the MM / GBSA method and re-scored and sorted according to the MM / GBSA ΔG bind score<-50kcal / mol to screen out compounds with high binding free energy scores.
6. The virtual screening method according to claim 1, characterized in that: Between step (4) and step (5), the method further includes classifying and grouping the compounds with the highest binding free energy scores obtained in step (4); The classification and grouping includes: structural classification of compounds in the Ligand Filtering module according to the functional group type, and then selecting compounds with high binding free energy scores to perform molecular dynamics simulation in step (5).
7. The virtual screening method according to claim 1 or 6, characterized in that: In step (5), the molecular dynamics simulation uses the Binding Pose Metadynamics module. Each protein-ligand docking complex undergoes a round of 10×10 ns molecular dynamics simulation. The complexes are sorted again from small to large according to the CompScore values obtained from the simulation, and the top-ranked molecules are screened as potentially active compounds.
8. Use of compounds a5, a6, a7, a10, b4, b9, b11, d2, d3, d10, d29 or pharmaceutically acceptable salts thereof having the following structures in the preparation of STAT3 inhibitors:
9. Use of compounds a5, a6, a7, a10, b4, b9, b11, d2, d3, d10, d29 or pharmaceutically acceptable salts thereof having the following structures in the preparation of drugs for treating and / or preventing diseases associated with abnormal STAT3 activity:
10. The use according to claim 9, characterized in that: The diseases are breast cancer, gastric cancer, prostate cancer, lung cancer, and pancreatic cancer.
Citation Information
Patent Citations
Virtual screening method for anti-inflammatory, anti-tumor and anti-immunization drug targeting STING
CN109461474A
TIPE2 inhibitor as well as application, screening method and screening device thereof
CN114224892A
Small molecule inhibitors of STAT3 with anti-tumor activity
US20090069420A1
VHR protein tyrosine phosphatase inhibitors, compositions and methods of use
US20090105254A1
Methods for screening antimicrobial and antiviral compounds and uses thereof
WO2008066576A2
Cited By
Ultrahigh-flux drug small molecule virtual screening method, storage medium and equipment
CN119889520A
